دورية أكاديمية
Recent Advancement in mRNA Vaccine Development and Applications.
| العنوان: | Recent Advancement in mRNA Vaccine Development and Applications. |
|---|---|
| المؤلفون: | Al Fayez N; Advanced Diagnostics and Therapeutics Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia., Nassar MS; Advanced Diagnostics and Therapeutics Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia., Alshehri AA; Advanced Diagnostics and Therapeutics Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia., Alnefaie MK; Advanced Diagnostics and Therapeutics Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia., Almughem FA; Advanced Diagnostics and Therapeutics Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia., Alshehri BY; Advanced Diagnostics and Therapeutics Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia., Alawad AO; Healthy Aging Research Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia., Tawfik EA; Advanced Diagnostics and Therapeutics Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia. |
| المصدر: | Pharmaceutics [Pharmaceutics] 2023 Jul 18; Vol. 15 (7). Date of Electronic Publication: 2023 Jul 18. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101534003 Publication Model: Electronic Cited Medium: Print ISSN: 1999-4923 (Print) Linking ISSN: 19994923 NLM ISO Abbreviation: Pharmaceutics Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI |
| مستخلص: | Messenger RNA (mRNA) vaccine development for preventive and therapeutic applications has evolved rapidly over the last decade. The mRVNA vaccine has proven therapeutic efficacy in various applications, including infectious disease, immunotherapy, genetic disorders, regenerative medicine, and cancer. Many mRNA vaccines have made it to clinical trials, and a couple have obtained FDA approval. This emerging therapeutic approach has several advantages over conventional methods: safety; efficacy; adaptability; bulk production; and cost-effectiveness. However, it is worth mentioning that the delivery to the target site and in vivo degradation and thermal stability are boundaries that can alter their efficacy and outcomes. In this review, we shed light on different types of mRNA vaccines, their mode of action, and the process to optimize their development and overcome their limitations. We also have explored various delivery systems focusing on the nanoparticle-mediated delivery of the mRNA vaccine. Generally, the delivery system plays a vital role in enhancing mRNA vaccine stability, biocompatibility, and homing to the desired cells and tissues. In addition to their function as a delivery vehicle, they serve as a compartment that shields and protects the mRNA molecules against physical, chemical, and biological activities that can alter their efficiency. Finally, we focused on the future considerations that should be attained for safer and more efficient mRNA application underlining the advantages and disadvantages of the current mRNA vaccines. |
| References: | Expert Rev Vaccines. 2017 Sep;16(9):871-881. (PMID: 28701102) Nature. 2020 Sep;585(7823):107-112. (PMID: 32728218) Carbohydr Polym. 2016 Oct 5;150:308-18. (PMID: 27312642) Proc Natl Acad Sci U S A. 2017 Mar 7;114(10):E1941-E1950. (PMID: 28202722) Annu Rev Biomed Eng. 2022 Jun 6;24:85-109. (PMID: 35231177) Immunity. 2005 Aug;23(2):165-75. (PMID: 16111635) Eur Rev Med Pharmacol Sci. 2021 Jun;25(12):4405-4412. (PMID: 34227076) Nature. 2021 Aug;596(7872):417-422. (PMID: 34192737) Hum Vaccin Immunother. 2013 Oct;9(10):2263-76. (PMID: 23921513) Eur J Immunol. 2000 Jan;30(1):1-7. (PMID: 10602021) Molecules. 2018 Dec 13;23(12):. (PMID: 30551668) Cancer Discov. 2022 May 2;12(5):1248-1265. (PMID: 35176764) Adv Drug Deliv Rev. 2021 Mar;170:1-25. (PMID: 33359141) Hum Vaccin Immunother. 2021 Jun 3;17(6):1612-1621. (PMID: 33242386) Nat Rev Genet. 2017 May;18(5):272-273. (PMID: 28366936) Mol Ther. 2008 Nov;16(11):1833-40. (PMID: 18797453) Pharmaceut Med. 2022 Feb;36(1):11-20. (PMID: 35094366) Nat Struct Mol Biol. 2015 Mar;22(3):256-64. (PMID: 25664725) Age Ageing. 2021 Feb 26;50(2):279-283. (PMID: 33320183) Nat Rev Genet. 2008 Oct;9(10):776-88. (PMID: 18781156) Small. 2019 Feb;15(6):e1805097. (PMID: 30637934) Pharmaceutics. 2022 Feb 11;14(2):. (PMID: 35214130) Gene Ther. 2021 Apr;28(3-4):117-129. (PMID: 33093657) Viruses. 2016 Jun 11;8(6):. (PMID: 27294951) Mol Ther. 2021 Jun 2;29(6):1970-1983. (PMID: 33823303) Adv Drug Deliv Rev. 2021 Mar;170:83-112. (PMID: 33400957) Nat Commun. 2020 Sep 8;11(1):4464. (PMID: 32900994) Adv Healthc Mater. 2023 Jun;12(15):e2202688. (PMID: 36785927) Int J Nanomedicine. 2020 Nov 06;15:8673-8696. (PMID: 33192061) Nanomaterials (Basel). 2020 Feb 20;10(2):. (PMID: 32093140) Biochim Biophys Acta. 2001 Feb 9;1510(1-2):152-66. (PMID: 11342155) Nucleic Acids Res. 2016 Feb 18;44(3):1370-83. (PMID: 26657629) Science. 2022 Nov 25;378(6622):899-904. (PMID: 36423275) Biomaterials. 2018 Feb;156:172-193. (PMID: 29197748) Vaccines (Basel). 2021 Jan 19;9(1):. (PMID: 33478109) J Am Chem Soc. 2009 Feb 4;131(4):1384-5. (PMID: 19133723) J Am Chem Soc. 2018 May 9;140(18):5987-5999. (PMID: 29676910) Angew Chem Int Ed Engl. 2021 Mar 8;60(11):5848-5853. (PMID: 33305471) MMWR Morb Mortal Wkly Rep. 2021 Apr 02;70(13):495-500. (PMID: 33793460) Drug Metab Pharmacokinet. 2021 Dec;41:100424. (PMID: 34757287) Cell. 2017 Mar 9;168(6):1114-1125.e10. (PMID: 28222903) Int J Pharm. 2021 Jan 25;593:120080. (PMID: 33246046) J Med Virol. 2023 Feb;95(2):e28572. (PMID: 36762592) Genes Dev. 1991 Nov;5(11):2108-16. (PMID: 1682219) Angew Chem Int Ed Engl. 2022 Jan 10;61(2):e202113671. (PMID: 34694684) N Engl J Med. 2021 Apr 15;384(15):1412-1423. (PMID: 33626250) Nat Rev Mater. 2021;6(12):1078-1094. (PMID: 34394960) J Allergy Clin Immunol. 2016 Mar;137(3):868-78. (PMID: 26452420) Science. 2020 Jul 3;369(6499):77-81. (PMID: 32376603) Nat Nanotechnol. 2018 Mar;13(3):214-219. (PMID: 29379205) Mol Pharm. 2020 Dec 7;17(12):4421-4434. (PMID: 33213144) J Am Chem Soc. 2022 Jun 8;144(22):9926-9937. (PMID: 35616998) Int J Mol Sci. 2020 Sep 09;21(18):. (PMID: 32916818) Paediatr Int Child Health. 2021 Feb;41(1):36-55. (PMID: 32584199) Nat Nanotechnol. 2020 May;15(5):406-416. (PMID: 32123380) Adv Drug Deliv Rev. 2019 Apr;144:90-111. (PMID: 31419450) Cell Death Dis. 2022 Jul 23;13(7):644. (PMID: 35871216) Mol Ther. 2021 Nov 3;29(11):3293-3304. (PMID: 34091054) Gene Ther. 2010 Aug;17(8):961-71. (PMID: 20410931) Int J Mol Sci. 2023 Jan 31;24(3):. (PMID: 36769023) RNA. 2003 Sep;9(9):1108-22. (PMID: 12923259) Genome Med. 2017 Jun 27;9(1):60. (PMID: 28655327) Viruses. 2018 Feb 28;10(3):. (PMID: 29495654) Nat Rev Drug Discov. 2014 Oct;13(10):759-80. (PMID: 25233993) MedComm (2020). 2022 Aug 25;3(3):e167. (PMID: 36033422) J Control Release. 2021 May 10;333:511-520. (PMID: 33798667) Pharmaceutics. 2022 Jun 15;14(6):. (PMID: 35745843) J Control Release. 2014 Sep 10;189:141-9. (PMID: 24995949) Nat Biotechnol. 2011 Feb;29(2):154-7. (PMID: 21217696) Int J Mol Sci. 2022 Oct 25;23(21):. (PMID: 36361673) Nat Biotechnol. 2023 Feb;41(2):262-272. (PMID: 35851375) Nature. 2020 Oct;586(7830):589-593. (PMID: 32785213) Alzheimers Dement (N Y). 2021 Feb 05;7(1):e12126. (PMID: 33598529) Expert Opin Drug Deliv. 2019 Nov;16(11):1149-1167. (PMID: 31498013) Pharmaceutics. 2021 Jun 14;13(6):. (PMID: 34198550) Mol Cell. 2019 May 2;74(3):508-520.e4. (PMID: 30902547) Nat Commun. 2018 Jul 6;9(1):2629. (PMID: 29980667) ACS Nano. 2019 Apr 23;13(4):3754-3782. (PMID: 30908008) Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):520-5. (PMID: 26729861) Nat Rev Drug Discov. 2020 Feb;19(2):112-129. (PMID: 31554928) Eur J Pediatr. 2002 Jan;161(1):21-5. (PMID: 11808876) Cell Mol Life Sci. 2019 Jan;76(2):301-328. (PMID: 30334070) Saudi Pharm J. 2023 Jul;31(7):1139-1148. (PMID: 37273265) Sci Adv. 2020 Aug 07;6(32):eaba5068. (PMID: 32821824) Small. 2018 Sep;14(36):e1802081. (PMID: 30102454) Nano Lett. 2018 Oct 10;18(10):6449-6454. (PMID: 30211557) Lancet Infect Dis. 2018 Jul;18(7):e211-e219. (PMID: 29396004) Nat Rev Genet. 2014 Aug;15(8):541-55. (PMID: 25022906) Nat Chem. 2022 Mar;14(3):274-283. (PMID: 35115657) Nat Biotechnol. 2012 Dec;30(12):1202-4. (PMID: 23222788) Nat Biotechnol. 2022 Jun;40(6):840-854. (PMID: 35534554) J Virol. 2000 Oct;74(20):9776-85. (PMID: 11000254) Eur J Immunol. 2004 Feb;34(2):537-47. (PMID: 14768059) Pharmaceutics. 2023 Apr 03;15(4):. (PMID: 37111613) Nat Med. 2021 Nov;27(11):2025-2031. (PMID: 34526698) J Control Release. 2016 Oct 28;240:227-234. (PMID: 26718856) Clin Chem. 2002 Oct;48(10):1647-53. (PMID: 12324479) N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609) Vaccines (Basel). 2021 Sep 17;9(9):. (PMID: 34579270) Drug Deliv Transl Res. 2020 Jun;10(3):678-689. (PMID: 32048201) Nano Lett. 2020 Jul 8;20(7):5167-5175. (PMID: 32496069) Drug Deliv. 2016 Sep;23(7):2596-2607. (PMID: 26024387) Mol Ther. 2017 Jul 5;25(7):1467-1475. (PMID: 28412170) Proc Natl Acad Sci U S A. 2020 May 26;117(21):11727-11734. (PMID: 32376634) Front Oncol. 2023 Mar 10;13:1132319. (PMID: 36969060) Vaccine. 2021 Mar 5;39(10):1478-1480. (PMID: 33558107) Clin Vaccine Immunol. 2009 Dec;16(12):1709-19. (PMID: 19793898) Nat Rev Drug Discov. 2018 Apr;17(4):261-279. (PMID: 29326426) Methods Mol Biol. 2017;1499:109-121. (PMID: 27987145) N Engl J Med. 2021 Sep 16;385(12):1078-1090. (PMID: 34432976) Science. 2021 Aug 20;373(6557):882-889. (PMID: 34413232) Proc Natl Acad Sci U S A. 2022 Aug 23;119(34):e2207841119. (PMID: 35969778) Nat Rev Drug Discov. 2021 Nov;20(11):817-838. (PMID: 34433919) NPJ Vaccines. 2020 Feb 14;5(1):16. (PMID: 32128257) Nano Lett. 2017 Mar 8;17(3):1326-1335. (PMID: 28273716) JAMA Netw Open. 2020 Oct 1;3(10):e2025594. (PMID: 33079199) Nat Rev Genet. 2022 May;23(5):265-280. (PMID: 34983972) Lancet Oncol. 2022 Oct;23(10):e450-e458. (PMID: 36174631) Adv Healthc Mater. 2017 Jul;6(13):. (PMID: 28436620) Nature. 2017 Mar 9;543(7644):248-251. (PMID: 28151488) Nat Commun. 2018 Oct 29;9(1):4493. (PMID: 30374059) Gene Ther. 2018 Oct;25(7):473-484. (PMID: 30154525) Sci Adv. 2020 Nov 18;6(47):. (PMID: 33208369) Front Bioeng Biotechnol. 2021 Jul 27;9:718753. (PMID: 34386486) Curr Opin Immunol. 2020 Aug;65:14-20. (PMID: 32244193) J Control Release. 2016 Apr 28;228:9-19. (PMID: 26941035) PLoS Negl Trop Dis. 2016 Jun 23;10(6):e0004746. (PMID: 27336830) Nucleic Acids Res. 2017 Jun 2;45(10):6023-6036. (PMID: 28334758) J Immunother Cancer. 2022 Jun;10(6):. (PMID: 35688554) Sci Adv. 2022 Feb 25;8(8):eabm7950. (PMID: 35196075) J Am Chem Soc. 2021 Nov 3;143(43):17975-17982. (PMID: 34672554) Mol Ther. 2019 Apr 10;27(4):710-728. (PMID: 30846391) Bioconjug Chem. 2016 Mar 16;27(3):849-53. (PMID: 26906521) NPJ Vaccines. 2022 Dec 13;7(1):161. (PMID: 36513697) J Control Release. 2016 Aug 10;235:222-235. (PMID: 27266364) Nanomaterials (Basel). 2021 Jun 07;11(6):. (PMID: 34200384) Nano Lett. 2021 Oct 27;21(20):8563-8570. (PMID: 34647460) Colloids Surf B Biointerfaces. 2021 May;201:111633. (PMID: 33639513) Eur J Immunol. 2006 Oct;36(10):2807-16. (PMID: 17013976) Nat Rev Cancer. 2021 Sep;21(9):558-577. (PMID: 34341537) Pharmaceutics. 2020 Jan 28;12(2):. (PMID: 32013049) Methods Mol Biol. 2017;1499:15-35. (PMID: 27987141) Cell Rep. 2016 Aug 9;16(6):1485-1491. (PMID: 27481466) Wien Klin Wochenschr. 2021 Sep;133(17-18):931-941. (PMID: 34378087) JAMA. 2021 Mar 16;325(11):1101-1102. (PMID: 33576785) Nat Biotechnol. 2022 Aug;40(8):1160-1162. (PMID: 35945442) Cell Rep. 2018 Dec 18;25(12):3382-3392.e3. (PMID: 30566864) Proc Natl Acad Sci U S A. 1989 Aug;86(16):6077-81. (PMID: 2762315) Vaccines (Basel). 2021 Feb 12;9(2):. (PMID: 33673131) Mol Ther Methods Clin Dev. 2020 Jul 21;18:702-712. (PMID: 32913878) Vaccines (Basel). 2021 Jan 23;9(2):. (PMID: 33498787) Langmuir. 2021 Jan 26;37(3):1120-1128. (PMID: 33439022) NPJ Vaccines. 2020 Feb 4;5:11. (PMID: 32047656) Nature. 2020 Jul;583(7816):459-468. (PMID: 32353859) N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246) Nat Commun. 2017 Mar 02;8:14630. (PMID: 28251988) Signal Transduct Target Ther. 2022 May 21;7(1):166. (PMID: 35597779) J Immunother Cancer. 2019 Feb 8;7(1):38. (PMID: 30736848) Annu Rev Med. 2022 Jan 27;73:17-39. (PMID: 34669432) Cell Host Microbe. 2021 Apr 14;29(4):508-515. (PMID: 33789086) Nat Biotechnol. 2019 Oct;37(10):1174-1185. (PMID: 31570898) |
| فهرسة مساهمة: | Keywords: cancer; delivery; immune response; infectious diseases; lipid nanoparticles (LNPs); mRNA vaccine |
| تواريخ الأحداث: | Date Created: 20230729 Latest Revision: 20230801 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10384963 |
| DOI: | 10.3390/pharmaceutics15071972 |
| PMID: | 37514158 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1999-4923 |
|---|---|
| DOI: | 10.3390/pharmaceutics15071972 |